<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18311">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895010</url>
  </required_header>
  <id_info>
    <org_study_id>ESA2013</org_study_id>
    <nct_id>NCT01895010</nct_id>
  </id_info>
  <brief_title>Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE</brief_title>
  <official_title>Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observation on acupoint electric stimulation combined with tropisetron in preventing and
      treating nausea and vomiting and improving the patient's appetite after TACE for primary or
      metastatic liver cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Classification of nausea and vomiting, as measured by NCI CTC-AE version 3

        -  The improvement of appetite, as measure by the classification of Appetite in accordance
           with NCI CTC-AE version 3.

        -  Quality of life: use M. D. Anderson symptom scale (the m. d. Anderson Symptom
           Inventory,MDASI)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Classification of nausea and vomiting</measure>
    <time_frame>12 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The improvement of appetite</measure>
    <time_frame>12 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <condition>Metastatic Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Acupoint  and tropisetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acupoint electric stimulation combined with tropisetron 6mg before TACE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tropisetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treated with tropisetron 6mg before TACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>acupoint electric stimulation</intervention_name>
    <description>acupoint electric stimulation combined with tropisetron 6mg before TACE</description>
    <arm_group_label>Acupoint  and tropisetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tropisetron</intervention_name>
    <description>only tropisetron 6mg before TACE</description>
    <arm_group_label>tropisetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG physical status 0,1,2

          -  would accept the transcatheter hepatic arterial chemoembolization of primary or
             metastatic liver cancer patients;

          -  Adult male and female 3, age 18 years old;

          -  the chem-scheme of arterial infusion chemotherapy based on oxaliplatin dosage of
             200mg;

          -  signed the informed consent and understand the study design;

          -  Organ function examination in patients must meet the following laboratory indexes:
             Neutrophil&gt;500/Ul, hemoglobin &gt; 8 gm/dL, platelet &gt;100000/uL,Creatinine &lt; 2 mg/dL
             bilirubin &lt; 1.5 mg/dL, , alanine aminotransferase &lt; 3 times the normal value, albumin
             &gt;30g/L

          -  understand and complete quality of life scale ;

          -  women of childbearing age urine pregnancy test was negative.

        Exclusion Criteria:

          -  The combined use of other venous chemotherapy within 5 days after TACE;

          -  skin infection on or near the points;

          -  skin hyperalgesia, unable to withstand electrical stimulation;

          -  other confounding factors may cause nausea and vomiting (such as intestinal
             obstruction, anorexia, etc.);

          -  heart, cerebrovascular accident history or the history of spinal cord injury;

          -  intestinal obstruction lead to nausea and vomiting

          -  installing pacemaker;

          -  cognitive dysfunction, unable to finish Scale;

          -  currently using acupuncture therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoyan Zhu, Doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Cancer Centre, Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Zhu, Dotral</last_name>
      <phone>+08602164175590</phone>
      <phone_ext>3625</phone_ext>
      <email>zhuxiaoyan@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaoyan Zhu, doc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 9, 2013</lastchanged_date>
  <firstreceived_date>June 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>zhu xiao yan</investigator_full_name>
    <investigator_title>Attending doctor</investigator_title>
  </responsible_party>
  <keyword>prevention and treatment</keyword>
  <keyword>improvement of the patient's appetite</keyword>
  <keyword>TACE</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tropisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
